Kimberly Guerrero shares stories about the action-packed climax of the Stephen King prequel series, which brings the whole ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. The latest high-profile crossovers—which include a starry TV partnership and the ...

Eli Lilly’s stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement ...

The stock recently reached beyond $1,000. Investors generally don't turn to pharmaceutical stocks with expectations of high growth in a short period of time. Instead, they scoop up these players for ...

The Influencer Lilly Gaddis has claimed that her YouTube channel has been demonetized for being “too pro-White.” Gaddis, who has a following of over 240,000 on X and over 60,000 on Instagram, ...

Eli Lilly & Co.’s stock has reached new highs in recent days, becoming the first pharmaceutical company to hit a $1 trillion valuation. The surge has also lifted the founding family’s private ...

Pharmaceutical company Eli Lilly is looking to roll out a daily weight loss pill for patients with obesity and type 2 diabetes. A recent trial showed the drug enabled people with both conditions to ...

Eli Lilly is upgraded to a "Strong Buy" due to 54% revenue growth, driven by Zepbound and Mounjaro's success in obesity and T2D. The company is expanding its pipeline with Orforglipron [oral GLP-1 ...